HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.

Détails

Ressource 1Télécharger: 31911409_pp_cover.pdf (2595.10 [Ko])
Etat: Public
Version: Author's accepted manuscript
Licence: Non spécifiée
ID Serval
serval:BIB_992D4D3B538A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.
Périodique
BMJ case reports
Auteur⸱e⸱s
Nunes M.B., Rotman S., Duss F.R., Halfon M.
ISSN
1757-790X (Electronic)
ISSN-L
1757-790X
Statut éditorial
Publié
Date de publication
06/01/2020
Peer-reviewed
Oui
Volume
13
Numéro
1
Pages
e231844
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: epublish
Résumé
Multicentric Castleman disease is a rare polyclonal lymphoproliferative disorder mainly associated with two renal manifestations: thrombotic microangiopathy and amyloidosis. Nevertheless, we report here a case of human herpes virus-8 negative multicentric Castleman disease with membranous proliferative glomerulonephritis and extracapillary proliferation. A patient was successfully treated with corticosteroids, anti-CD20 and cyclophosphamide therapy.
Mots-clé
Adrenal Cortex Hormones/therapeutic use, Antigen-Antibody Complex, Castleman Disease/complications, Castleman Disease/drug therapy, Cyclophosphamide/therapeutic use, Diagnosis, Differential, Drug Therapy, Combination, Glomerulonephritis, Membranoproliferative/drug therapy, Glomerulonephritis, Membranoproliferative/etiology, Herpesvirus 8, Human, Humans, Immunologic Factors/therapeutic use, Immunosuppressive Agents/therapeutic use, Male, Middle Aged, Rituximab/therapeutic use, acute renal failure, proteinurea
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2020 11:23
Dernière modification de la notice
21/11/2022 8:28
Données d'usage